卵巢癌多药耐药^(99m)Tc-MIBI显像的研究现状及临床应用进展  

Development of ^(99m)Tc-MIBI scintigraphy in multidrug resistance of ovarian cancer

作　　者：王芬[1] 刘楠楠[1] 申东兰[1] 

机构地区：[1]北京大学深圳医院肿瘤科,广东深圳518036

出　　处：《现代肿瘤医学》2009年第7期1372-1375,共4页Journal of Modern Oncology

基　　金：深圳市卫生局科技计划项目基金资助(编号:JH200505270418B)

摘　　要：卵巢癌多药耐药(MDR)是导致化疗失败的一个重要原因,无创性诊断卵巢癌多药耐药一直是临床研究热点。其作用机制主要与P糖蛋白(P-gp)、MRP相关蛋白(MRP)及肺耐药蛋白(LRP)等有关。甲氧基异丁基异腈(MIBI)是P-gp、MRP共同的转运底物,细胞内99mTc-MIBI的摄取浓度与细胞上MDR表达的功能状态成反比。因此利用99mTc-MIBI功能显像对卵巢癌定性诊断、评价多药耐药及预测化疗效果,指导临床选择个体化的治疗方案可能有很高的临床应用价值。Multidrug resistance to the chemotherapy is one of the main reasons of failure of treatment in ovarian cancer. Non - invasive diagnosis for ovarian cancer is hot topic of clinical researches. Mechanism of multidrug resistance for ovarian cancer frequently link to P - glucose protein （ P - gp ）, multidrug resistance - associated protein （MRP） ,lung resistance protein（LRP） and so on. ^99mTc -MIBI is a transmission substrate of P-gp and MRP. Uptake concentrations on ^99mTc - MIBI in the cell is revealed with the state of MDR. ^99mTc - MIBI seintigraphy has high clinical value on ovarian cancer diagnosis, multidrug resistance evaluation, chemotherapy effect prediction and offer theoretical basis for individual therapy.

关 键 词：99MTC-MIBI 卵巢癌 多药耐药 

分 类 号：R737.31[医药卫生—肿瘤]